Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Establishment Labs Holdings stock

ESTA
VGG312491084
A2JRE4

Price

42.87
Today +/-
+0.33
Today %
+0.80 %

Establishment Labs Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Establishment Labs Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Establishment Labs Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Establishment Labs Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Establishment Labs Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Establishment Labs Holdings Stock Price History

DateEstablishment Labs Holdings Price
2/27/202542.87 undefined
2/26/202542.53 undefined
2/25/202536.06 undefined
2/24/202535.78 undefined
2/23/202535.21 undefined
2/20/202533.43 undefined
2/19/202535.03 undefined
2/18/202536.09 undefined
2/17/202535.38 undefined
2/13/202536.08 undefined
2/12/202533.59 undefined
2/11/202530.16 undefined
2/10/202530.33 undefined
2/9/202530.15 undefined
2/6/202528.51 undefined
2/5/202530.27 undefined
2/4/202530.80 undefined
2/3/202530.73 undefined
2/2/202529.94 undefined

Establishment Labs Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Establishment Labs Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Establishment Labs Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Establishment Labs Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Establishment Labs Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Establishment Labs Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Establishment Labs Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Establishment Labs Holdings’s growth potential.

Establishment Labs Holdings Revenue, EBIT and net profit per share

DateEstablishment Labs Holdings RevenueEstablishment Labs Holdings EBITEstablishment Labs Holdings Net Income
2028e529.99 M undefined95.37 M undefined43.13 M undefined
2027e397.6 M undefined46.51 M undefined34.84 M undefined
2026e261.93 M undefined-13.23 M undefined-30.9 M undefined
2025e210.37 M undefined-29.4 M undefined-53.57 M undefined
2024e169.52 M undefined-42.36 M undefined-69.97 M undefined
2023165.15 M undefined-65.03 M undefined-78.5 M undefined
2022161.7 M undefined-39.7 M undefined-75.2 M undefined
2021126.7 M undefined-25.1 M undefined-41.1 M undefined
202084.7 M undefined-27.9 M undefined-38.1 M undefined
201989.6 M undefined-30.9 M undefined-38.2 M undefined
201861.2 M undefined-23.9 M undefined-21.1 M undefined
201734.7 M undefined-20 M undefined-34.9 M undefined
201619.8 M undefined-15.8 M undefined-22.2 M undefined
20159.6 M undefined-400,000 undefined-1.6 M undefined

Establishment Labs Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e
91934618984126161165169210261397529
-111.1178.9579.4145.90-5.6250.0027.782.482.4224.2624.2952.1133.25
55.5652.6350.0059.0260.6761.9067.4665.8464.2462.7250.4840.6126.7020.04
510173654528510610600000
-1-22-34-21-38-38-41-75-78-69-53-303443
-2,100.0054.55-38.2480.95-7.8982.934.00-11.54-23.19-43.40-213.3326.47
17.917.917.920.420.523.32424.525.600000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Establishment Labs Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Establishment Labs Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
0.510.952.637.784.553.466.440.04
6.613.117.622.819.124.435.446.92
0001.20.60.61.41.07
4.813.224.828.723.228.436.679.47
0.62.24.35.64.96.410.27.4
12.539.499.396132.3113.2150174.9
13.213.512.916.418.820.954.880.59
00000000
00000000
2.13.43.43.44.14.44.67.99
300500500500500500500465
1.50.30.30.40.70.61.34.7
17.117.717.120.724.126.461.293.74
29.657.1116.4116.7156.4139.6211.2268.64
               
7.141.3145.7147.7213.5219.7223.6315.63
32815.221.226.736.649.963.75
-33-67.9-89-127.1-165.2-206.4-281.6-360.1
00.10.40.72.93.72.71.96
00000000
-22.91.572.342.577.953.6-5.421.25
7.39.16.210.49.714.52041.62
62.75.810.414.416.217.213.58
2.321.94.12.21.61.21.71.95
33.323.4000000
5.60.30.30.30.2000
54.557.416.423.325.931.938.957.15
0022.348.149.851.9175.5188.74
00000000
1.44.78.35.55.754.84.36
1.44.730.653.655.556.9180.3193.1
55.962.14776.981.488.8219.2250.25
3363.6119.3119.4159.3142.4213.8271.5
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Establishment Labs Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Establishment Labs Holdings's financial health and stability.

Assets

Establishment Labs Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Establishment Labs Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Establishment Labs Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Establishment Labs Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-22-34-21-38-38-41-75-78
01233334
0000000-3
-1-14-14-412-6-21-34
121851615265338
02556655
00000022
-14-31-33-29-12-27-52-88
-100-1-7-3-6-34-24
-100-5-7-5-7-34-24
00-30-1000
00000000
2322-52400960
-220880654386
2042812264410086
-1.00--1.00-2.00----
00000000
-41041-1446-3112-26
-24.82-32.91-35.66-36.98-16.42-34.26-86.44-113.06
00000000

Establishment Labs Holdings stock margins

The Establishment Labs Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Establishment Labs Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Establishment Labs Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Establishment Labs Holdings's sales revenue. A higher gross margin percentage indicates that the Establishment Labs Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Establishment Labs Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Establishment Labs Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Establishment Labs Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Establishment Labs Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Establishment Labs Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Establishment Labs Holdings Margin History

Establishment Labs Holdings Gross marginEstablishment Labs Holdings Profit marginEstablishment Labs Holdings EBIT marginEstablishment Labs Holdings Profit margin
2028e64.78 %17.99 %8.14 %
2027e64.78 %11.7 %8.76 %
2026e64.78 %-5.05 %-11.8 %
2025e64.78 %-13.98 %-25.47 %
2024e64.78 %-24.99 %-41.27 %
202364.78 %-39.37 %-47.53 %
202265.92 %-24.55 %-46.51 %
202167.4 %-19.81 %-32.44 %
202061.98 %-32.94 %-44.98 %
201961.27 %-34.49 %-42.63 %
201858.99 %-39.05 %-34.48 %
201751.01 %-57.64 %-100.58 %
201651.01 %-79.8 %-112.12 %
201552.08 %-4.17 %-16.67 %

Establishment Labs Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Establishment Labs Holdings earnings per share therefore indicates how much revenue Establishment Labs Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Establishment Labs Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Establishment Labs Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Establishment Labs Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Establishment Labs Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Establishment Labs Holdings Revenue, EBIT and net profit per share

DateEstablishment Labs Holdings Sales per ShareEstablishment Labs Holdings EBIT per shareEstablishment Labs Holdings Earnings per Share
2028e18.93 undefined0 undefined1.54 undefined
2027e14.2 undefined0 undefined1.24 undefined
2026e9.35 undefined0 undefined-1.1 undefined
2025e7.51 undefined0 undefined-1.91 undefined
2024e6.05 undefined0 undefined-2.5 undefined
20236.45 undefined-2.54 undefined-3.07 undefined
20226.6 undefined-1.62 undefined-3.07 undefined
20215.28 undefined-1.05 undefined-1.71 undefined
20203.64 undefined-1.2 undefined-1.64 undefined
20194.37 undefined-1.51 undefined-1.86 undefined
20183 undefined-1.17 undefined-1.03 undefined
20171.94 undefined-1.12 undefined-1.95 undefined
20161.11 undefined-0.88 undefined-1.24 undefined
20150.54 undefined-0.02 undefined-0.09 undefined

Establishment Labs Holdings business model

Establishment Labs Holdings Inc. is a leading medical device manufacturer based in Costa Rica. The company was founded in 2004 by Juan José Chacón and Salvador Dada and has experienced strong growth since then. It is listed on the NASDAQ under the ticker ESTA since 2018. The company focuses on the development and manufacture of products that help women improve their beauty and health. Some of the most commonly offered products by Establishment Labs include breast implants, botulinum toxin injections, and hyaluronic acid fillers. These products are used by doctors and plastic surgeons worldwide. Establishment Labs' business model is based on the development of innovative products that adhere to the highest quality standards. The company invests heavily in research and development to ensure that its products are safe and effective. It also pursues a differentiated strategy to stand out from other providers. Most competitors have products that are based on leak-prone cohesive silicone gels or non-cohesive saline solutions. However, Establishment Labs has developed a patented technology based on ultra-cohesive silicone gels, which are supposed to be softer and have a lower leakage rate. The company is divided into two main segments: the breast implant market and the disposable injection market. In the breast implant market, Establishment Labs is a significant competitor to breast implant market leaders such as Allergan and Mentor. The company has also started entering the disposable injection market, focusing on the development of hyaluronic acid fillers. Establishment Labs' breast implants are manufactured under the name Motiva. Motiva implants are available in over 60 countries worldwide. They feature a variety of functions aimed at improving the health and comfort of patients. Some notable features include a nano-textured surface that allows for better integration; a circumferential self-sealing technology that offers higher resistance to ruptures and air inclusion and higher breaking recovery capacity; and a "TrueMonobloc" technology that enables implants made consistently from a single material, reducing the risk of contamination, capsular contracture, and ruptures. Establishment Labs has also recently introduced a custom 3D printer system that allows surgeons to customize the shape and size of breast implants for each patient. The disposable injection market is also a significant growth area for Establishment Labs. The company has recently acquired the license to sell Q-Med products in Mexico and is currently developing its own hyaluronic acid-based filler. The company also plans to enter the market for botulinum toxin injections in the future. Overall, Establishment Labs is an emerging medical technology company that focuses on the development of high-quality products for aesthetic surgery. The company has a strong research and development department and a differentiated strategy that allows it to stand out from the competition and establish a strong presence in a growing market. Establishment Labs Holdings is one of the most popular companies on Eulerpool.com.

Establishment Labs Holdings SWOT Analysis

Strengths

Establishment Labs Holdings Inc has several strengths that position it positively in the market. These include:

  • A strong and experienced management team that brings expertise and strategic direction to the company.
  • Innovative and high-quality product offerings, including advanced breast implant technologies.
  • A strong brand reputation built on delivering safe and effective medical solutions.
  • Established relationships with healthcare professionals and distributors, providing a wide market reach.

Weaknesses

Despite its strengths, Establishment Labs Holdings Inc faces certain weaknesses that may hinder its growth and success:

  • Relatively high production costs associated with maintaining stringent quality standards and compliance measures.
  • Dependence on a limited number of suppliers for critical components, increasing vulnerability to supply chain disruptions.
  • Limited geographic presence, primarily focused on select markets, which may restrict potential revenue streams.

Opportunities

Establishment Labs Holdings Inc has several opportunities for expansion and market growth:

  • Increasing demand for breast implant technologies in both developed and emerging markets.
  • Expanding product portfolio to include a broader range of cosmetic and reconstructive solutions.
  • Capitalizing on the trend toward minimally invasive procedures by developing innovative non-surgical options.
  • Exploring strategic partnerships or acquisitions to enhance market presence and access new customer segments.

Threats

Several threats exist in the external environment that may impact Establishment Labs Holdings Inc:

  • Intense competition from established players and new entrants in the medical device industry.
  • Stringent regulatory requirements and potential changes in government policies that could impact product approvals and market access.
  • Public perception or safety concerns related to breast implant technologies that may negatively influence consumer demand.
  • Economic downturns or market volatility that could affect consumer spending on elective medical procedures.

Establishment Labs Holdings Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Establishment Labs Holdings Revenue by Segment

DateAsia-PacificAsia-Pacific/Middle EastEMEA (Europe / Middle East / Africa)EuropeLatin AmericaOther Countries
202333.95 M USD-80.15 M USD-48.89 M USD2.16 M USD
2022-59.56 M USD-48.7 M USD52.44 M USD994,000 USD
2021-35.68 M USD-51.91 M USD38.23 M USD865,000 USD
2020-24.99 M USD-37.67 M USD21.51 M USD511,000 USD
2019-24.82 M USD-36.21 M USD27.99 M USD540,000 USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Establishment Labs Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Establishment Labs Holdings historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Establishment Labs Holdings shares outstanding

The number of shares was Establishment Labs Holdings in 2024 — This indicates how many shares 25.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Establishment Labs Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Establishment Labs Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Establishment Labs Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Establishment Labs Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Establishment Labs Holdings.

Establishment Labs Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.63 -0.59  (5.95 %)2024 Q3
6/30/2024-0.52 -0.62  (-18.73 %)2024 Q2
3/31/2024-0.68 -0.58  (14.93 %)2024 Q1
12/31/2023-0.93 -0.79  (15 %)2023 Q4
9/30/2023-0.82 -1.12  (-37.14 %)2023 Q3
6/30/2023-0.73 -0.65  (10.96 %)2023 Q2
3/31/2023-0.69 -0.48  (30.8 %)2023 Q1
12/31/2022-0.69 -0.55  (20.51 %)2022 Q4
9/30/2022-0.55 -0.76  (-37.09 %)2022 Q3
6/30/2022-0.41 -1.52  (-274.38 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Establishment Labs Holdings stock

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

81

👫 Social

93

🏛️ Governance

71

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees48
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Establishment Labs Holdings shareholders

%
Name
Stocks
Change
Date
11.04459 % JW Asset Management, LLC3,092,485-100,00012/31/2024
9.17745 % RTW Investments L.P.2,569,687-76,01612/31/2024
8.35132 % Brown Advisory2,338,369438,05712/31/2024
6.82688 % Capital Research Global Investors1,911,525433,48412/31/2024
6.26897 % Qatar Investment Authority1,755,3111,755,31111/7/2024
5.90882 % Nantahala Capital Management, LLC1,654,470-704,67112/31/2024
4.80886 % Findell Capital Management LLC1,346,480318,38012/31/2024
4.02951 % Sariel, L.L.C.1,128,264012/31/2024
3.95804 % Lewin Nicholas Sheridan1,108,25254212/31/2024
3.62468 % Summit Partners Public Asset Management, LLC1,014,910543,80112/31/2024
1
2
3
4
5
...
10

Establishment Labs Holdings Executives and Management Board

Mr. Juan Jose Chacon Quiros

(51)
Establishment Labs Holdings Chief Executive Officer, Director (since 2013)
Compensation 2.58 M

Mr. S. Ross Mansbach

(56)
Establishment Labs Holdings Chief Compliance Officer, General Counsel
Compensation 1.49 M

Mr. Rajbir Denhoy

(53)
Establishment Labs Holdings Chief Financial Officer
Compensation 1.08 M

Mr. Nicholas Lewin

(46)
Establishment Labs Holdings Non-Executive Chairman of the Board
Compensation 625,402

Ms. Ann Custin

(63)
Establishment Labs Holdings Independent Director
Compensation 498,422
1
2

Establishment Labs Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Avantor Stock
Avantor
SupplierCustomer0,740,57-0,15-0,190,170,81
PolyNovo Stock
PolyNovo
SupplierCustomer0,49-0,62-0,26-0,230,66-0,27
1

Most common questions regarding Establishment Labs Holdings

What values and corporate philosophy does Establishment Labs Holdings represent?

Establishment Labs Holdings Inc represents a strong set of values and corporate philosophy. The company is dedicated to providing innovative medical technology solutions with a focus on safety and aesthetic outcomes. Their commitment to patient satisfaction is evident in their portfolio of breast and body aesthetic products. Establishment Labs Holdings Inc prioritizes quality, striving to meet rigorous standards and gaining regulatory approvals. With a customer-centric approach, the company aims to deliver state-of-the-art, personalized solutions that elevate patient experiences. By continuously investing in research and development, Establishment Labs Holdings Inc remains at the forefront of the industry, delivering excellence and transforming lives.

In which countries and regions is Establishment Labs Holdings primarily present?

Establishment Labs Holdings Inc is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where it is headquartered. Additionally, Establishment Labs Holdings Inc has significant operations in Europe, with a focus on countries like France, Germany, Spain, Italy, and the United Kingdom. The company also has a presence in Latin America, particularly in Brazil, Colombia, Mexico, and Argentina. With its expanding international reach, Establishment Labs Holdings Inc continues to establish its footprint in the global market, driving growth and innovation in the field of medical aesthetics.

What significant milestones has the company Establishment Labs Holdings achieved?

Establishment Labs Holdings Inc has achieved significant milestones since its establishment. Some notable achievements include receiving FDA approval for the Motiva Implants® line, which offers cutting-edge technology for breast augmentation and reconstruction. The company has expanded its global presence by securing regulatory approvals in various countries, further enhancing its market reach. Establishment Labs Holdings Inc has also fostered collaborations with renowned plastic surgeons and academic institutions to continually advance its innovative medical solutions. These achievements highlight the company's commitment to revolutionizing the aesthetics industry and improving patient outcomes.

What is the history and background of the company Establishment Labs Holdings?

Establishment Labs Holdings Inc is a renowned global medical device company that specializes in breast aesthetics and reconstruction technologies. Founded in 2004, the company has established itself as a leading player in the field, offering innovative products and solutions that cater to the specific needs of patients and healthcare professionals. With a focus on safety, aesthetics, and patient satisfaction, Establishment Labs has earned a strong reputation worldwide. As a publicly traded company, it operates with a commitment to excellence, continually advancing its technologies and expanding its global footprint. With its dedication to quality and innovation, Establishment Labs Holdings Inc continues to make significant contributions to the medical aesthetics industry.

Who are the main competitors of Establishment Labs Holdings in the market?

The main competitors of Establishment Labs Holdings Inc in the market include other leading companies in the medical aesthetics industry, such as Allergan Plc, Sientra Inc, and Johnson & Johnson. These companies also offer a range of aesthetic products and solutions, and compete with Establishment Labs in terms of product innovation, market share, and customer base.

In which industries is Establishment Labs Holdings primarily active?

Establishment Labs Holdings Inc is primarily active in the aesthetic and medical device industries.

What is the business model of Establishment Labs Holdings?

The business model of Establishment Labs Holdings Inc is focused on designing, manufacturing, and marketing medical devices and breast implants for aesthetic and reconstructive surgeries. The company specializes in the Motiva Implant Matrix, a highly innovative and advanced silicone breast implant technology. Establishment Labs aims to provide safe, high-quality, and aesthetically pleasing solutions to meet the evolving needs of surgeons and patients globally. Through continuous research and development, they strive to expand their product portfolio and enhance patient outcomes. With a strong emphasis on innovation and customer satisfaction, Establishment Labs is committed to delivering excellence in the field of aesthetic and reconstructive surgery.

What is the P/E ratio of Establishment Labs Holdings 2025?

The Establishment Labs Holdings P/E ratio is -20.49.

What is the P/S ratio of Establishment Labs Holdings 2025?

The Establishment Labs Holdings P/S ratio is 5.22.

What is the Quality Investing of Establishment Labs Holdings?

The Quality Investing for Establishment Labs Holdings is 3/10.

What is the revenue of Establishment Labs Holdings 2025?

The expected Establishment Labs Holdings revenue is 210.37 M USD.

How high is the profit of Establishment Labs Holdings 2025?

The expected Establishment Labs Holdings profit is -53.57 M USD.

What is the business model of Establishment Labs Holdings

Establishment Labs Holdings Inc is a leading company in the medical aesthetics industry. The company's business model is based on the manufacturing and distribution of breast implants, as well as the provision of complementary plastic surgery products and technologies. One of the focuses of Establishment Labs Holdings is the manufacturing of round, anatomically shaped, and textured silicone gel breast implants. These products are sold under the brand Motiva and offer a wide range of sizes and shapes to meet individual patient needs and preferences. Motiva implants are known for their high quality, durability, and safety, and are available in over 70 countries worldwide. In addition to breast implants, Establishment Labs Holdings offers a range of complementary products, including the MatrixChamber mattress overlay manufactured in Full HD technology. This technology is also used in a variety of surgical instruments distributed by the company. The technological advancements achieved by Establishment Labs Holdings can be attributed to its innovative and dedicated team of researchers and developers. The company heavily invests in research and development to create new technologies and products that benefit both patients and physicians. Another important aspect of Establishment Labs Holdings' business model is its collaboration with a network of certified plastic surgeons in various countries. The company offers training and educational opportunities for surgeons interested in using Motiva implants and other products from Establishment Labs Holdings. This ensures that its products are being used by qualified professionals and also provides a high level of customer service and support for patients. In addition to offering medical products and technologies, Establishment Labs Holdings is committed to social responsibility. The company is dedicated to sustainability and environmental friendliness and is certified as carbon-neutral and for sustainable value creation. In summary, the business model of Establishment Labs Holdings Inc is focused on providing high-quality medical products and technologies to plastic surgeons and patients worldwide. Through its focused research and development efforts, collaboration with qualified professionals, and commitment to sustainability, the company is well positioned to meet the constantly evolving needs and demands of the medical aesthetics industry.

What is the Establishment Labs Holdings dividend?

Establishment Labs Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Establishment Labs Holdings pay dividends?

The dividend cannot currently be calculated for Establishment Labs Holdings or the company does not pay out a dividend.

What is the Establishment Labs Holdings ISIN?

The ISIN of Establishment Labs Holdings is VGG312491084.

What is the Establishment Labs Holdings WKN?

The WKN of Establishment Labs Holdings is A2JRE4.

What is the Establishment Labs Holdings ticker?

The ticker of Establishment Labs Holdings is ESTA.

How much dividend does Establishment Labs Holdings pay?

Over the past 12 months, Establishment Labs Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Establishment Labs Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Establishment Labs Holdings?

The current dividend yield of Establishment Labs Holdings is .

When does Establishment Labs Holdings pay dividends?

Establishment Labs Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Establishment Labs Holdings?

Establishment Labs Holdings paid dividends every year for the past 0 years.

What is the dividend of Establishment Labs Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Establishment Labs Holdings located?

Establishment Labs Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Establishment Labs Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Establishment Labs Holdings from 3/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/2/2025.

When did Establishment Labs Holdings pay the last dividend?

The last dividend was paid out on 3/2/2025.

What was the dividend of Establishment Labs Holdings in the year 2024?

In the year 2024, Establishment Labs Holdings distributed 0 USD as dividends.

In which currency does Establishment Labs Holdings pay out the dividend?

The dividends of Establishment Labs Holdings are distributed in USD.

All fundamentals about Establishment Labs Holdings

Our stock analysis for Establishment Labs Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Establishment Labs Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.